Abstract:Background Our previous studies revealed a critical role of a novel CTLA4-protein kinase C-eta (PKCη) signaling axis in mediating the suppressive activity of regulatory T cells (Tregs) in antitumor immunity. These studies have employed adoptive transfer of germline PKCη-deficient ( Prkch −/− ) Tregs into Prkch +/+ mice prior to tumor implantation. Here, we extended these findings into a biologically and clinically more relevant context. Methods We have analyzed the role of PKCη in antitumor immunity and the tumor microenvironment (TME) in intact tumor-bearing mice with Treg-specific or CD8 + T cell-specific Prkch deletion, including in a therapeutic model of combinatorial treatment. In addition to measuring tumor growth, we analyzed the phenotype and functional attributes of tumor-infiltrating immune cells, particularly Tregs and dendritic cells (DCs). Results Using two models of mouse transplantable cancer and a genetically engineered autochthonous hepatocellular carcinoma (HCC) model, we found, first, that mice with Treg-specific Prkch deletion displayed a significantly reduced growth of B16–F10 melanoma and TRAMP-C1 adenocarcinoma tumors. Tumor growth reduction was associated with a less immunosuppressive TME, indicated by increased numbers and function of tumor-infiltrating CD8 + effector T cells and elevated expression of the costimulatory ligand CD86 on intratumoral DCs. In contrast, CD8 + T cell-specific Prkch deletion had no effect on tumor growth or the abundance and functionality of CD8 + effector T cells, consistent with findings that Prkch −/− CD8 + T cells proliferated normally in response to in vitro polyclonal or specific antigen stimulation. Similar beneficial antitumor effects were found in mice with germline or Treg-specific Prkch deletion that were induced to develop an autochthonous HCC. Lastly, using a therapeutic model, we found that monotherapies consisting of Treg-specific Prkch deletion or vaccination with irradiated Fms-like tyrosine kinase 3 ligand (Flt3L)-expressing B16–F10 tumor cells post-tumor implantation significantly delayed tumor growth. This effect was more pronounced in mice receiving a combination of the two immunotherapies. Conclusion These findings demonstrate the potential utility of PKCη inhibition as a viable clinical approach to treat patients with cancer, especially when combined with adjuvant therapies.

Peripheral-derived regulatory T cells contribute to tumor-mediated immune suppression in a nonredundant manner

Regulatory T cells crosstalk with tumor and endothelium through lymphotoxin signaling

Precise Spatiotemporal Interruption of Regulatory T-cell-Mediated CD8(+) T-cell Suppression Leads to Tumor Immunity

Acquisition of suppressive function by conventional T cells limits antitumor immunity upon Treg depletion

Regulatory T cells in tumor immunity

Blockade of Surface-Bound Tgf-Beta on Regulatory T Cells Abrogates Suppression of Effector T Cell Function in the Tumor Microenvironment

Immunoregulatory T cells in tumor immunity

Profile of Regulatory T Cells and Interferon Γ Secretion in the Tumor-Draining Lymph Node from Mouse Hepa1–6 Cells

Abstract 723: Reduction of immunosuppressive function of regulatory T cells enhances antigen-specific T cell mediated cytotoxicity against tumor cells

Leveraging the Treg-intrinsic CTLA4–PKCη signaling pathway for cancer immunotherapy

Downregulation of TCF7 and LEF1 is a key determinant of tumor-infiltrating regulatory T-cell function

Regulatory T cells regulate function of effector T lymphocytes in tumor-draining lymph node of mouse hepatocelluar carcinoma

The PTEN Pathway in Tregs is a Critical Driver of the Suppressive Tumor Microenvironment

Regulatory T Cells: Barriers of Immune Infiltration Into the Tumor Microenvironment

Regulatory T cells in tumor microenvironment: new mechanisms, potential therapeutic strategies and future prospects

Abstract 2919: Targeting regulatory T cells to boost immunity against melanoma

Regulatory T (Treg) cells in cancer: Can Treg cells be a new therapeutic target?

Circulating tumor-reactive KIR + CD8 + T cells suppress anti-tumor immunity in patients with melanoma

Regulatory T cells in cancer immunosuppression — implications for anticancer therapy

Human hepatocellular carcinoma-infiltrating CD4 + CD69 + Foxp3 − regulatory T cell suppresses T cell response via membrane-bound TGF-β1

Immunotherapy of Cancer by Targeting Regulatory T cells